Drug reference
Telenzepine
Antimuscarinic · Antiulcer Agent
AntimuscarinicAntiulcer Agent
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Telenzepine is an M1 muscarinic receptor antagonist, structurally an analog of pirenzepine, with higher potency and similar M1 selectivity. It acts as an inverse agonist, shifting muscarinic receptors to an inactive state to prevent acetylcholine binding and subsequent effects like inositol trisphosphate (IP3) release and adenylyl cyclase inhibition. Telenzepine suppresses neural stimulation of gastric acid production by acting on M1 receptors located in intramural ganglia.
Indications
Acid-peptic diseasePeptic ulcer diseasePeptic ulcer disease (used in Europe, Japan, and Canada, not in the U.S.)
Dosing
- Adult
- In the doses usually used, atropine has minimal stimulant effects on the CNS, especially the parasympathetic medullary centers, and a slower, longer lasting sedative effect on the brain. Scopolamine has more marked central effects, producing drowsiness when given in recommended dosages and amnesia in sensitive individuals that may be mediated via the histamine H3 receptor.…
Contraindications
- Rarely used today due to poor efficacy and significant side effects
Side effects
Common
XerostomiaLoss of visual accommodationPhotophobiaDifficulty in urinationSignificant and undesirable anticholinergic side effects
Serious
- Blood disorders
Related guidelines
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Coeliac disease
OTHER · Gastroenterology · 2016
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Gastric premalignant conditions
ACG · Gastroenterology · 2025
Other Antimuscarinic drugs
Ask House about Telenzepine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team